Shire’s antihemophilic Adynovate trails Bayer’s Kovaltry into Latin America

GBI analysis shows that Takeda subsidiary Shire’s Adynovate (rurioctocog alfa pegol) this week obtained market clearance from Brazil’s National Health Surveillance Agency (ANVISA). While the agency has not yet published indication details, the injectable drug is used to treat patients with hemophilia A (congenital factor VIII deficiency).

Adynovate is a PEGylated form of a recombinant full-length human coagulation factor VIII designed to temporarily replace the missing clotting factor VIII that is needed for effective hemostasis. Its PEGylation reduces binding to the physiological factor VIII clearance receptor (LRP1), thus extending Adynovate’s half-life compared to parent molecule Advate (octocog alfa), marketed by Takeda.

According to GBI analysis, ANVISA’s is the first regulatory approval that Adynovate obtains in Latin America, although Advate is present in the markets of Argentina, Brazil, Chile, Colombia, Ecuador, and Mexico. Adynovate’s registration comes only one week after the approval of competitor Bayer’s Kovaltry (octocog beta) in Brazil, which also marked its entrance into the region.


Related news
China-based contract manufacturing organization (CMO) WuXi Biologics Inc., (HKEX.2269) announced that is has signed an acquisition agreement with Germany-based major Bayer AG, under which WuXi Bio will take over the operations of one of Bayer’s final drug product manufacturing plants in Leverkusen, Germany.
Germany-based Bayer this week obtained marketing approval from Brazil’s National Health Surveillance Agency (ANVISA) for its hemophilia treatment Kovaltry (octocog beta), according to GBI analysis.
CSL Behring, a wholly owned subsidiary of Australia-based CSL Ltd, this week received registration approval from Brazil’s National Health Surveillance Agency (ANVISA) for its antihemorrhagic Afstyla (lonoctocog alfa), according to GBI analysis.
China’s Center for Drug Evaluation (CDE) has made a series of priority review filing decisions, with four products from multinational corporations on the list. Those are: Bristol-Myers Squibb (BMS)’s programmed death-1 (PD-1) inhibitor Opdivo (nivolumab); Novartis’ psoriasis therapy Cosentyx (secukinumab); Novo Nordisk’s antihemophilic Novoeight (recombinant Factor VIII); and Boehringer Ingelheim’s multi-kinase inhibitor Ofev (nintedanib), a treatment for idiopathic pulmonary fibrosis (IPF). Apart from Novoeight, the other three products all have existing market approvals in China.
  • 1565082543262
  • China
  • Drug
As first reported by GBI last week, China has moved to reduce the value-added tax (VAT) payable on rare disease drugs in China.
Recent news
China’s Center for Drug Evaluation (CDE) published the 27th chemical generic reference preparations list, soliciting public feedback from January 20 to February 5.
China’s Sino Biopharmaceutical Ltd (HKEX.01177) announced that subsidiary Nanjing Chia Tai Weikang Biopharmaceutical Co., Ltd (GBI translation) has entered into a marketing agreement with Switzerland-based Octapharma AG.
China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA:600196; HKG:02196) subsidiary Shanghai Henlius Pharmaceutical Co., Ltd (HKG.02696) announced clinical approval from the National Medical Products Administration (NMPA) in relation to its recombinant anti-HER2 domain II monoclonal antibody (mAb) HLX11, a biosimilar of Swiss giant Roche’s Perjeta (pertuzumab).
  • 1579664967786
  • China
  • Drug
Beigene Ltd released a press release announcing its successful bid for Abraxane paclitaxel (nanoparticle ablumin-bound) during the recently completed second round of the volume-based procurement (VBP) program.
US major Eli Lilly’s type 2 diabetes drug candidate tirzepatide (LY3298176) has obtained 6 tacit clinical trial approvals from the Center for Drug Evaluation (CDE), according to the bureau’s website.
China-based biotech BeiGene Ltd (Nasdaq.BGNE) announced that a Phase III clinical study for the programmed death-1 (PD-1) antibody tislelizumab in combination with two chemotherapies reached primary endpoint in a Phase III study as a first-line treatment for squamous non-small cell lung cancer (sqNSCLC).
  • 1579661419502
  • China
  • Drug
Hangzhou-based Gmax Biopharm LLC picked up a tacit clinical trial approval for GMA301, a Class 1 recombinant anti-human endothelin receptor A monoclonal antibody (mAb).
Analytics Snapshot

Analytics Snapshot